CDK12: a potential therapeutic target in cancer

被引：25

作者：

Emadi, Fatemeh ^{[1
]}

Teo, Theodosia ^{[1
]}

Rahaman, Muhammed H. ^{[1
]}

Wang, Shudong ^{[1
]}

机构：

[1] Univ South Australia, UniSA Clin & Hlth Sci, Drug Discovery & Dev, Adelaide, SA 5000, Australia

来源：

DRUG DISCOVERY TODAY | 2020年 / 25卷 / 12期

关键词：

D O I：

10.1016/j.drudis.2020.09.035

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cyclin-dependent kinase (CDK) 12 engages in diversified biological functions, from transcription, post-transcriptional modification, cell cycle, and translation to cellular proliferation. Moreover, it regulates the expression of cancer-related genes involved in DNA damage response (DDR) and replication, which are responsible for maintaining genomic stability. CDK12 emerges as an oncogene or tumor suppressor in different cellular contexts, where its dysregulation results in tumorigenesis. Current CDK12 inhibitors are nonselective, which impedes the process of pharmacological target validation and drug development. Herein, we discuss the latest understanding of the biological roles of CDK12 in cancers and provide molecular analyses of CDK12 inhibitors to guide the rational design of selective inhibitors.

引用

页码：2257 / 2267

页数：11

共 120 条

[1] A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition [J].

Alagpulinsa, David A. ;

Ayyadevara, Srinivas ;

Yaccoby, Shmuel ;

Reis, Robert J. Shmookler .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (02) :241-250

[2]

[Anonymous], 2017, TUMOUR BIOL, V39, P1

[3]

Antonarakis ES, 2020, JCO PRECIS ONCOL, V4, P370, DOI [10.1200/PO.19.00399, 10.1200/po.19.00399]

[4] CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway [J].

Bai, Ning ss ;

Fada, Xia ;

Wang, Wenlong ;

Lei, Yao ;

Bo, Jiang ;

Li, Xinying .

JOURNAL OF CANCER, 2020, 11 (15) :4308-4315

[5] Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity [J].

Bajrami, Ilirjana ;

Frankum, Jessica R. ;

Konde, Asha ;

Miller, Rowan E. ;

Rehman, Farah L. ;

Brough, Rachel ;

Campbell, James ;

Sims, David ;

Rafiq, Rumana ;

Hooper, Sean ;

Chen, Lina ;

Kozarewa, Iwanka ;

Assiotis, Ioannis ;

Fenwick, Kerry ;

Natrajan, Rachael ;

Lord, Christopher J. ;

Ashworth, Alan .

CANCER RESEARCH, 2014, 74 (01) :287-297

[6] The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia [J].

Baker, Adele ;

Gregory, Gareth P. ;

Verbrugge, Inge ;

Kats, Lev ;

Hilton, Joshua J. ;

Vidacs, Eva ;

Lee, Erwin M. ;

Lock, Richard B. ;

Zuber, Johannes ;

Shortt, Jake ;

Johnstone, Ricky W. .

CANCER RESEARCH, 2016, 76 (05) :1158-1169

[7] CDK12 Activity-Dependent Phosphorylation Events in Human Cells [J].

Bartkowiak, Bartlomiej ;

Yan, Christopher M. ;

Soderblom, Erik J. ;

Greenleaf, Arno L. .

BIOMOLECULES, 2019, 9 (10)

[8] Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex [J].

Bartkowiak, Bartlomiej ;

Greenleaf, Arno L. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (03) :1786-1795

[9] CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1 [J].

Bartkowiak, Bartlomiej ;

Liu, Pengda ;

Phatnani, Hemali P. ;

Fuda, Nicholas J. ;

Cooper, Jeffrey J. ;

Price, David H. ;

Adelman, Karen ;

Lis, John T. ;

Greenleaf, Arno L. .

GENES & DEVELOPMENT, 2010, 24 (20) :2303-2316

[10] Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma [J].

Bayles, Ian ;

Krajewska, Malgorzata ;

Pontius, W. Dean ;

Saiakhova, Alina ;

Morrow, James J. ;

Bartels, Cynthia ;

Lu, Jim ;

Faber, Zachary J. ;

Fedorov, Yuriy ;

Hong, Ellen S. ;

Karnuta, Jaret M. ;

Rubin, Brian ;

Adams, Drew J. ;

George, Rani E. ;

Scacheri, Peter C. .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10) :4377-4392

← 1 2 3 4 5 6 7 8 9 10 →